谷歌浏览器插件
订阅小程序
在清言上使用

Hybrid Arteriovenous Graft for Hemodialysis Vascular Access in a Multicenter Registry.

Filippo Benedetto,Domenico Spinelli,Narayana Pipito,Mirko Menegolo,Matteo Tozzi, Michele Giubbolini,Umberto Marcello Bracale,Dalmazio Frigerio,Andrea Agostinucci, Antonino Scolaro,Angela Alibrandi,Carlo Pratesi,Carlo Setacci, Graziana Derone, Franco Grego,Marco Franchin,Gabriele Piffaretti, Patrizio Castelli, Walter Morale, Elena Giacomelli, Alessandro Alessi Innocenti, Giulia Mazzitelli, Giambattista Gagliardo

Journal of vascular surgery(2019)

引用 5|浏览26
暂无评分
摘要
Objective: The aim of our study was to identify patients' characteristics that predicted a higher chance of arteriovenous graft patency in patients undergoing Gore Hybrid Vascular Graft (GHVG; W. L. Gore & Associates, Flagstaff, Ariz) implantation for hemodialysis access. The GHVG is a polytetrafluroethylene (PTFE) prosthesis with a nitinol-reinforced section (NRS) at the venous end. Methods: All consecutive patients undergoing GHVG implantation for hemodialysis access at 10 tertiary referral centers between December 2013 and January 2018 were included in the study and compared with a control group of patients undergoing standard PTFE graft implantation. Selection of patients for hybrid graft implantation was based on the impossibility of autogenous vascular access creation. Results: There were 145 patients included in the GHVG group and 218 in the PTFE group. In the GHVG and the PTFE groups, the mean age was 67 +/- 13 years and 65 +/- 13 years, and male patients totaled 52% and 46%, respectively. The technical success was 99%. The mean duration of the intervention was 100 minutes (median, 95 minutes; interquartile range, 80-120 minutes). The brachial-axillary configuration was used in the majority of cases (n = 78 [54%]). The 5-cm NRS length was prevalent (n = 108 [75%]). The median NRS oversize was 14% (interquartile range, 0%-21%). Mean follow-up was 13 months (range, 0-55 months). Seventy-one patients (49%) underwent at least one reintervention. Primary, assisted primary, and secondary patency estimates at 12 months were 44% +/- 5%, 47% +/- 5%, and 65% +/- 4% for the GHVG group and 41% +/- 4%, 53% +/- 4%, and 75% +/- 3% for the control group, respectively (P = NS). One-year survival was 90% +/- 3%. On multivariable Cox regression analysis, hypotension (P<.001; hazard ratio [HR], 5.8; confidence interval [CI], 2.6-13) and diabetes (P=.024; HR, 1.9; CI, 1.1-3.2) were significant predictors of GHVG loss. A larger graft size was protective against GHVG loss (P=.042; HR, 0.73; CI, 0.54-0.99). The 10-cm-long graft showed a tendency toward improved patency but did not reach statistical significance (P=.074; HR, 0.48; CI, 0.21-1.07). Conclusions: Diabetes and hypotension were predictors of loss of hybrid arteriovenous access. Smaller diameters of NRS were more prone to thrombosis, whereas the 10-cm length seemed to perform better than the 5-cm one.
更多
查看译文
关键词
Vascular hybrid graft,Arteriovenous graft,Patency,Nitinol-reinforced section,Hemodialysis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要